Free Trial

Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Should You Sell?

Merck KGaA logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Shares gapped down before the market opened, dropping from $127.76 to an opening price of $122.41 and later trading at $130.06 on very light volume (123 shares).
  • The stock is trading below its 50‑day and 200‑day simple moving averages ($142.73 and $139.63) and has a market capitalization of $15.81 billion with a P/E ratio of 18.68.
  • Merck KGaA is a long-established (founded 1668) German chemical and pharmaceutical company, privately controlled by the Merck family and operating globally across multiple business units.
  • Five stocks to consider instead of Merck KGaA.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $127.7640, but opened at $122.41. Merck KGaA shares last traded at $130.0630, with a volume of 123 shares.

Merck KGaA Price Performance

The company has a fifty day simple moving average of $142.73 and a two-hundred day simple moving average of $139.63. The stock has a market capitalization of $15.81 billion, a price-to-earnings ratio of 18.68 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck KGaA Right Now?

Before you consider Merck KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.

While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before SpaceX Goes Public Cover

A forward-looking investment report spotlighting the seven space companies best positioned to benefit from accelerating commercialization in 2026. It explores key industry trends, major growth catalysts, and the stocks shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines